First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study

被引：3
|
作者：
Mok, Tony [1 ]
Schmid, Peter [2 ]
De Castro, Gilberto, Jr. [3 ]
Syrigos, Kostas [4 ]
Martin, Claudio [5 ]
Yamamoto, Nobuyuki [6 ]
Aren, Osvaldo [7 ]
Arrieta, Oscar [8 ]
Gottfried, Maya [9 ]
Jazieh, Abdul Rahman [10 ]
Ramlau, Rodryg [11 ]
Timcheva, Constanta [12 ]
Trani, Leonardo [13 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[2] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[3] Fac Med Usp, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[4] Univ Athens, Athens, Greece
[5] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
[6] Wakayama Med Univ, Dept Expt Therapeut Internal Med Resp Med & Med O, Wakayama, Japan
[7] Ciec Ctr Int Estudios Clin, Dept Oncol, Santiago, Chile
[8] Inst Nacl Cancerol Incan, Thorac Oncol Unit, Mexico City, DF, Mexico
[9] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
[10] King Saud Univ Hlth Sci Natl Guards Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia
[11] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland
[12] Mhat Womens Hlth, Med Oncol Clin, Sofia, Bulgaria
[13] Astrazeneca, Royston, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MEDI4736; tremelimumab; durvalumab; Checkpoint blockade;
D O I：
10.1016/j.jtho.2016.11.1515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-022
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 50 条
  • [1] Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    de Castro, G., Jr.
    Syrigos, K.
    Martin, C.
    Yamamoto, N.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Trani, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    de Castro Jr, Gilberto
    Rizvi, Naiyer A.
    Schmid, Peter
    Syrigos, Konstantinos
    Martin, Claudio
    Yamamoto, Nobuyuki
    Cheng, Ying
    Moiseyenko, Vladimir
    Summers, Yvonne
    Vynnychenko, Ihor
    Lee, Sung Yong
    Bryl, Maciej
    Zer, Alona
    Erman, Mustafa
    Timcheva, Constanta
    Raja, Rajiv
    Naicker, Kirsha
    Scheuring, Urban
    Walker, Jill
    Mann, Helen
    Chand, Vikram
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
  • [3] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [4] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
    Thomas, M.
    Grohe, C.
    Eberhardt, W.
    Rawluk, J.
    Reck, M.
    Laack, E.
    Wesseler, C.
    Rittmeyer, A.
    Alt, J.
    Reinmuth, N.
    Griesinger, F.
    Kern, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
  • [5] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [6] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Therapy for metastatic NSCLC: Results of the Phase 3 POSEIDON Study
    Rawluk, J.
    Johnson, M. L.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Kim, S. -W
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. -T
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Medic, N.
    Peters, S.
    Garon, E.
    Mok, T. S. K.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 102 - 103
  • [7] Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Martin, C.
    Zhao, L.
    McIntosh, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [8] NEPTUNE China Cohort: First-Line Durvalumab plus Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
    Cheng, Y.
    Zhou, Q.
    Han, B.
    Fan, Y.
    Shan, L.
    Chang, J.
    Sun, S.
    Fang, J.
    Chen, Y.
    Sun, J.
    Wu, G.
    Mann, H.
    Naicker, K.
    Shire, N.
    Mok, T.
    De Castro, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S358 - S358
  • [9] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [10] A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
    Wu, Y-L.
    Lu, S.
    Clarke, S.
    Lactionov, K.
    Li, P.
    Kirkby, M.
    Xie, Y.
    Stockman, P.
    ANNALS OF ONCOLOGY, 2017, 28
12345